Journal of Neuro-Oncology

, Volume 99, Issue 2, pp 283–286 | Cite as

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

  • Jennifer L. Clarke
  • William Pao
  • Nian Wu
  • Vincent A. Miller
  • Andrew B. Lassman
Case Report

Abstract

Leptomeningeal metastases (LM) occur in 5–10% of patients with solid tumors and are associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a mutation in the epidermal growth factor receptor (EGFR) gene that confers sensitivity to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. The CSF concentration of EGFR-TKIs achieved by standard daily dosing may be insufficient for therapeutic effect. However, intermittent (pulsatile) high dose administration (1000–1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient.

Keywords

Leptomeningeal metastases EGFR Lung cancer Erlotinib 

Notes

Acknowledgements

Marissa Balak for EGFR mutational analysis; Joan’s Legacy, the Doris Duke Charitable Foundation, and the NIH for funding (WP); Lisa M. DeAngelis, MD and Ingo Mellinghoff, MD for critical review of the manuscript; Judith Lampron for invaluable editorial assistance.

Disclaimers

Drs. Pao and Miller report the following potential conflict of interest: a patent on EGFR T790M testing has been licensed on behalf of Drs. Pao, Miller, and others by MSKCC to MolecularMD.

References

  1. 1.
    DeAngelis LM, Posner JP (2009) Leptomeningeal metastases. In: DeAngelis LM, Posner JP (eds) Neurologic complications of cancer, 2nd edn. Oxford University Press, Inc, New York, pp 240–281Google Scholar
  2. 2.
    Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181CrossRefPubMedGoogle Scholar
  3. 3.
    Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Janne PA, Johnson BE (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520CrossRefPubMedGoogle Scholar
  4. 4.
    Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA (2006) A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034–1041CrossRefPubMedGoogle Scholar
  5. 5.
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311CrossRefPubMedGoogle Scholar
  6. 6.
    Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73CrossRefPubMedGoogle Scholar
  7. 7.
    Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267–3279PubMedGoogle Scholar
  8. 8.
    Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11:7841-7850 [published correction appears in Clin Cancer Res. 2005;7812(7841):7322]Google Scholar
  9. 9.
    Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14:485–493CrossRefPubMedGoogle Scholar
  10. 10.
    Dhruva N, Socinski MA (2009) Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 27:e31–e32CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Jennifer L. Clarke
    • 1
    • 2
  • William Pao
    • 3
    • 4
    • 5
  • Nian Wu
    • 6
  • Vincent A. Miller
    • 3
  • Andrew B. Lassman
    • 1
  1. 1.Department of Neurology and Brain Tumor CenterMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Neurological Surgery, Division of Neuro-OncologyUniversity of CaliforniaSan FranciscoUSA
  3. 3.Thoracic Oncology Service, Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Human Oncology and Pathogenesis ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.Vanderbilt-Ingram Cancer CenterNashvilleUSA
  6. 6.Program in PharmacologySloan-Kettering Institute, Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations